How Tumors Become Angiogenic

https://doi.org/10.1016/S0065-230X(08)60862-3Get rights and content

Publisher Summary

As normal cells progress to tumorigenicity, they must develop two distinct new characteristics not possessed by the normal cells from which they arise: they must become able to multiply without restraint and they must be able to create in vivo an environment where this newly acquired growth potential can be realized. Normal cells are antiangiogenic, because they secrete only low levels of inducers of angiogenesis and high levels of molecules that inhibit neovascularization. These cells develop into successful tumors that are potently angiogenic and secrete high levels of a cocktail of molecules that induce neovascularization. It is possible to halt the production and/or release of angiogenic activity by tumor cells themselves using retinoic acid and similar compounds. Endothelial cells that form the vessels that support tumor growth can be disabled in two distinct ways. Antiangiogenic agents have distinct advantages over conventional cytotoxic cancer therapies. Although the importance of angiogenesis to the growth of tumors is now well established, the mechanism by which tumor cells develop this crucial ability to attract new blood vessels is just beginning to be explored. Available data suggest that the angiogenic phenotype develops gradually as a result of many of the same genetic changes in oncogenes and tumor suppressor genes that are also responsible for the deregulation of cell growth. The inhibitors of angiogenesis offer a new and promising avenue for tumor therapy.

References (376)

  • F. Arnold et al.

    Pharmacol. Ther.

    (1991)
  • W. Auerbach et al.

    Pharmacol. Ther.

    (1994)
  • M. Azuma et al.

    Cancer Lett.

    (1994)
  • P. Bagavandoss et al.

    Biochem. Biophys. Res. Commun.

    (1990)
  • M. Ballin et al.

    Biochem. Biophys. Res Commun.

    (1988)
  • R. Bicknell et al.

    Eur. J. Cancer

    (1991)
  • W. Bollag et al.

    Ann. Oncol.

    (1992)
  • P.C. Brooks et al.

    Cell

    (1994)
  • L.F. Brown et al.

    Hum. Pathol.

    (1995)
  • C.A. Carter et al.

    Exp. Cell Res.

    (1994)
  • L.L. Chen et al.

    Biochem. Biophys. Res. Commun.

    (1993)
  • D.K. Chopin et al.

    J. Urol.

    (1993)
  • J. Denekamp et al.

    Eur. J. Cancer Clin. Oncol.

    (1983)
  • N. Ferrara et al.

    Biochem. Biophys. Res. Commun.

    (1989)
  • G. Fibbi et al.

    Exp. Cell Res.

    (1988)
  • J. Folkman

    Adv. Cancer Res.

    (1985)
  • S.S. Agarwala et al.

    Oncology

    (1994)
  • A. Albini et al.

    AIDS

    (1994)
  • A. Albini et al.

    Proc. natl. Acad. Sci. USA

    (1995)
  • G.H. Algire et al.

    J. natl. Cancer Inst.

    (1945)
  • T.I. Andersen et al.

    Genes Chromosom. Cancer

    (1992)
  • A.L. Angiolillo et al.

    J. Exp. Med.

    (1995)
  • R.L. Avery et al.

    Arch. Ophthalmol.

    (1990)
  • R.G. Azizkhan et al.

    Surg. Forum

    (1981)
  • S.A. Bader et al.

    Cell Growth Differ.

    (1991)
  • M.R. Bani et al.

    J. natl. Cancer Inst.

    (1991)
  • K. Barker et al.

    J. Virol.

    (1989)
  • R.L. Barnhill et al.

    Lab. Invest.

    (1992)
  • P. Basset et al.

    Breast Cancer Res. Treat

    (1993)
  • E.J. Battegay et al.

    J. Cell Biol.

    (1994)
  • S.M. Bell et al.

    Mol. Cell. Biol.

    (1993)
  • M.B. Berkenpas et al.

    Proc. natl. Acad. Sci. USA

    (1991)
  • R.A. Berkman et al.

    J. Clin. Invest.

    (1993)
  • M. Berman et al.

    Invest. Ophthalmol. Vis. Sci.

    (1982)
  • C. Betsholtz et al.

    Mol. Chem. Neuropathol.

    (1989)
  • E. Bianchi et al.

    Int. J. Cancer

    (1995)
  • R. Bicknell et al.

    Semin. Cancer Biol.

    (1992)
  • M.C. Birchenall-Roberts et al.

    Mol. Cell. Biol.

    (1990)
  • F.Z. Bischoff et al.

    Cancer Res.

    (1990)
  • F.Z. Bischoff et al.

    Oncogene

    (1991)
  • W. Bollag

    J. Cell. Biochem.

    (1994)
  • R. Bookstein et al.

    Science

    (1990)
  • E. Bossy-Wetzel et al.

    Genes Devel.

    (1992)
  • N. Bouck

    Cancer Cells

    (1990)
  • N. Bouck et al.

    Mol. Cell. Biol.

    (1982)
  • J.F. Boylan et al.

    Anticancer Res.

    (1990)
  • H. Brem et al.

    J. Cell Biol.

    (1991)
  • S.S. Brem et al.

    Cancer

    (1978)
  • P.C. Brooks et al.

    Science

    (1994)
  • D. Brouty-Boye et al.

    Science

    (1980)
  • Cited by (456)

    • Noninvasive, in vivo assessment of the cervical microcirculation using incident dark field imaging

      2021, Microvascular Research
      Citation Excerpt :

      By regulating the exchange of fluids and molecules, the microcirculation is responsible for tissue homeostasis and consequently tissue wellness (Guven et al., 2020). Accordingly, the microcirculation plays a crucial role in many pathological processes, including inflammation, sepsis, shock and tumor growth (Bouck et al., 1996; Guven et al., 2020). Likewise, the microcirculation of the uterine cervix is involved in its immune and tissue response to physiological and pathological conditions, including cervical ripening, cervicitis, infection with human papillomavirus, cervical dysplasia and cancer (Abdullaiev et al., 2017; Agrawal et al., 2020; Chen et al., 2004; D'Anna et al., 2001; Dunlop et al., 1989; Jourdan et al., 2011; Sotiropoulou et al., 2004).

    • Natural remedies and functional foods as angiogenesis modulators

      2020, Functional Foods in Cancer Prevention and Therapy
    • Cancer biology and other disorders: Beneficial role of camptothecin and novel derivatives

      2020, Camptothecin and Camptothecin Producing Plants: Botany, Chemistry, Anticancer Activity and Biotechnology
    View all citing articles on Scopus
    View full text